Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

ConclusionsThis study did not meet the predefined primary endpoint of changes in NT ‐proBNP levels, with 24 weeks of treatment with canagliflozin vs. glimepiride. Further research is warranted to determine whether patients with heart failure with preserved ejection fraction, regardless of diabetes status, could potentially benefit from treatment with SGLT2 inhibitors.

Source: ESC Heart Failure - April 28, 2020 Category: Cardiology Authors: Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun ‐ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node, on behalf of the CANDLE Trial Investigators Tags: Original Research Article Source Type: research